

Another US FDA approval in GE's portfolio

04 September 2014 | News | By BioSpectrum Bureau

Another US FDA approval in GE's portfolio

The United States Food and Drug Administration (US FDA) has approved GE healthcare's latest technology SenoClaire, a new tomosynthesis solution designed using three-dimensional imaging technology.

"With the FDA's approval of SenoClaire, we build on our breast care continuum which offers physicians and patients a complete suite of solutions, ranging from screening and diagnosis through treatment, and monitoring," said Ms Catherine Tabaka, chief marketing officer, detection and guidance solutions, GE Healthcare. She added, "SenoClaire not only offers patients a new solution to help clinicians better detect breast cancer, but does so with low dose radiation and high image quality. This new generation technology, breast tomosynthesis, together with innovative solutions like contrast enhanced spectral mammography, automated whole breast ultrasound, and molecular breast imaging will equip health care providers with a comprehensive set of tools that will help patients across the entire breast care continuum."

GE has developed this technology in collaboration with the Massachusetts General Hospital. "Today's announcement marks a key milestone in our mission of providing women with cutting edge screening technology to detect early breast cancer. When cancer is identified and treated earlier, we know women have a better rate of survival," said Dr Daniel Kopans, senior radiologist, breast imaging division, department of radiology, Massachusetts General Hospital.